Nutex Health (NUTX) Stock Price, News & Analysis

Company Overview

Nutex Health, Inc. (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care. Nutex Health’s telemedicine platform enables remote consultations, while its teleradiology division provides imaging interpretation services to partner clinics and hospitals. To address the growing demand for chronic condition management and lifestyle medicine, the company also offers medically supervised weight‐loss programs and mental health counseling.

Established through a series of strategic mergers and acquisitions beginning in 2021, Nutex Health has expanded its footprint across multiple regions in the United States. The company currently operates outpatient facilities in over a dozen states, with a particular focus on communities that lack convenient access to comprehensive healthcare services. Its growth strategy continues to emphasize bolt‐on acquisitions of regional clinic operators and investments in digital health technologies.

By integrating in‐person and virtual care channels, Nutex Health seeks to streamline the patient journey and reduce overall healthcare costs. The company’s leadership team comprises healthcare executives with backgrounds in ambulatory care management, digital health innovation and private‐equity‐backed rollup strategies. Nutex Health remains committed to expanding its service offerings and geographic reach to meet evolving patient needs and industry trends.

Key Stats

• Today's Range: $176.19 to $186.27
• 50-Day Range: $112.02 to $196.53
• 52-Week Range: $77.21 to $204.00
• Volume: 87,267 shs
• Average Volume: 178,916 shs
• Market Capitalization: $1.26 billion
• P/E Ratio: 14.06
• Dividend Yield: N/A
• Price Target: $243.33
• Consensus Rating: Moderate Buy

Nutex Health Stock Analysis - MarketRank™

Nutex Health scored higher than 58% of companies evaluated by MarketBeat, and ranked 152nd out of 844 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nutex Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Nutex Health has a consensus price target of $243.33, representing about 31.9% upside from its current price of $184.44.

Amount of Analyst Coverage

Nutex Health has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.25%

Earnings Growth

Earnings for Nutex Health are expected to grow by 6.25% in the coming year, from $22.72 to $24.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nutex Health is 14.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 46.11.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nutex Health is 14.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.37.

Price to Book Value per Share Ratio

Nutex Health has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.30% of the float of Nutex Health has been sold short.

Short Interest Ratio / Days to Cover

Nutex Health has a short interest ratio ("days to cover") of 8.31.

Change versus previous month

Short interest in Nutex Health has recently increased by 4.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nutex Health does not currently pay a dividend.

Dividend Growth

Nutex Health does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Nutex Health this week, compared to 8 articles on an average week.

Search Interest

5 people have searched for NUTX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Nutex Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nutex Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.68% of the stock of Nutex Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.32% of the stock of Nutex Health is held by institutions.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 7/09/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NUTX
• CIK: 1479681
• Web: www.nutexhealth.com
• Phone: (713) 660-0557
• Fax: 631-670-6780
• Employees: 1,150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nutex Health: $243.33
• High Price Target: $290.00
• Low Price Target: $205.00
• Potential Upside/Downside: +32.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $12.94
• Trailing P/E Ratio: 14.31
• Forward P/E Ratio: 8.10
• P/E Growth: N/A
• Net Income: $70.79 million
• Net Margins: 10.95%
• Pretax Margin: 28.42%
• Return on Equity: 23.50%
• Return on Assets: 10.47%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 3.14
• Quick Ratio: 3.12

Sales & Book Value

• Annual Sales: $875.26 million
• Price / Sales: 1.45
• Cash Flow: $12.66 per share
• Price / Cash Flow: 14.55
• Book Value: $59.88 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 6,880,000
• Free Float: 3,807,000
• Market Cap: $1.27 billion
• Optionable: Not Optionable
• Beta: 0.21